Covid-19 therapy with monoclonal antibodies

• Autor(a) principal: Silva, Gerlane Guedes Delfino da
• Data de Publicação: 2022
• Outros Autores: Felício, Isabela Motta, Oliveira, Lucas Nóbrega de, Santos, Aline Kely Felício de Sousa, Macêdo, Cibério Landim
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/31668
• topic: Covid-19; Anticuerpo Monoclonal; Inmunoterapia.; Covid-19; Monoclonal Antibody; Immunotherapy.; Covid-19; Anticorpo Monoclonal; Imunoterapia.

In December 2019, in the city of Wuhan, a new viral variant emerged causing an outbreak of respiratory syndrome of unknown origin. In parallel with this, several effective vaccines have been developed, as well as studies of drug candidates capable of limiting and preventing the replication of the virus are underway. This review aims to investigate in the scientific literature the use of possible treatment strategies of monoclonal antibodies against SARS-CoV-2 infection. A systematic review of the literature available in the PubMed, Scielo and ScienceDirect databases was carried out, using as descriptors: covid-19, monoclonal antibodies and immunotherapy published in Portuguese, English and Spanish, with a range from 2020 to 2022. Of the 638 studies found, 17 were selected. Neutralizing monoclonal antibody therapies targeting SARS-CoV-2 were considered promising potential therapies for Covid-19, belonging to different pharmacological classes such as spike protein inhibitors, IL-6 inhibitors, IL-1-β inhibitors, ACE2 inhibitors, NAMP neutralizers, anti-granulocyte-macrophage stimulating factor, anti-CD6 IgG1, but its large-scale production for clinical application is laborious, expensive and costly. In this way, the advances in immunotherapeutic treatments are notable, but it is also necessary to design and develop advanced protein production platforms in order to provide efficient monoclonal antibodies at an affordable cost in a short time.